Blurred Lines: VCs, CVCs, and IBs Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies

BIO Investor Forum

10/07/2014 - 10/08/2014

Life Sciences, Emerging Companies + Venture Capital, and IPOs

The Palace Hotel
2 New Montgomery Street
San Francisco, CA 94105

Michael J. O'Donnell

Michael J. O'Donnell

Sponsorship

Michael O’Donnell is a panelist at the 2014 BIO Investor Forum held in San Francisco.

His session will discuss how the recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than the path to full acquisition. This panel will discuss how temporary or permanent these shifts appear to be and the implications for biotech firms reaching out to the investment community.

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2018 Morrison & Foerster LLP. All rights reserved.